Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.

Shannon Stockton,Paul Catalano,Steven J Cohen,Barbara A Burtness,Edith P Mitchell,Efrat Dotan,Sam J Lubner,Pankaj Kumar,Mary F Mulcahy,George A Fisher, Theodore L Crandall,Al Benson

The oncologist（2023）

Cited 0|Views15
No score
Abstract
The addition of cixutumumab to paclitaxel in second-line therapy of metastatic esophageal/GEJ cancer was well tolerated but did not improve clinical outcomes relative to standard of care (ClinicalTrials.gov Identifier: NCT01142388).
More
Translated text
Key words
esophageal,gastroesophageal junction,insulin-like growth factor-1 receptor,xixutumumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined